Speakers
Christopher R. Flowers, MD, MS, FASCO
Division Head ad Interim, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John M O'Quimm Endowed Chair in Cancer Research
MD Anderson Cancer Center
Houston, TX
Christopher R. Flowers, MD, MS joined The University of Texas MD Anderson Cancer Center in August 2019 as Chair of the Department of Lymphoma/Myeloma and was appointed Division Head ad interim of Cancer Medicine in August 2020. Through the COVID-19 pandemic, Dr. Flowers’ leadership contributed to the institution’s recovery in patient volume while maintaining accelerated safety measures. Prior to MD Anderson, he was professor of Hematology and Oncology with a joint appointment in Biomedical Informatics at Emory University School of Medicine in Atlanta. During his tenure there, he served the Winship Cancer Institute as director of the Lymphoma Program for 13 years and as scientific director of Research Informatics for four years. An internationally recognized expert in lymphoma clinical care, epidemiology and outcomes research, Dr. Flowers is an innovator who has a passion for facilitating new drug development. He is an active clinician who conducts clinical research involving cancer outcomes, cancer informatics, and phase 1/2 trials, focusing on the clinical development of novel therapeutics for B-cell lymphomas. His broader research interests include patient-oriented research in lymphoma and computer microsimulation models and cost-effectiveness analyses aimed at developing strategies to individualize care for cancer patients and improve systems of care. His work has resulted in >300 peer-reviewed publications. He has received peer-reviewed funding from foundations and the NIH including leading multi-institutional team science grants such as the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study. The largest prospective study of lymphoma patients in the US.
Dr. Flowers has served in many capacities for national professional societies and was elected to membership in the American Society of Clinical Investigation. In 2018, he was named a Fellow of the American Society of Clinical Oncology (ASCO), and served as chair of both the ASCO guidelines on management of febrile neutropenia and ASCO Health Disparities Committee. In the American Society of Hematology, Dr. Flowers has served as educational co-chair for the annual meeting, a longstanding faculty member and co-director of the Clinical Research Training Institute, and Chair of the Committee on Promoting Diversity. In each of these roles, he has committed to training and developing new leaders in hematology and oncology clinical research.
Sergio A. Giralt, MD, FACP
Melvin Berlin Family Chair in Myeloma Research
Professor in Medicine, Weill Cornell Medical College
Deputy Head, Division of Hematologic Malignancies
Attending Physician, Adult BMT Service
Memorial Sloan Kettering Cancer Center
New York, NY
Sergio Giralt, M.D. - Professor of Medicine, Deputy Division Head of Hematologic Malignancies at Memorial Sloan-Kettering Cancer Center. His clinical research focus is on stem cell transplantation for patients with blood disorders. Dr Giralt trained and worked at the University of Texas M.D. Anderson Cancer Center, where he was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies. In May 2010, he joined the faculty of Memorial Sloan-Kettering Cancer Center to lead the Adult Bone Marrow Transplant Service and served as Chief until February 2020.
Sanjay K. Juneja, MD
Chief of Oncology Line
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Dr. Sanjay Juneja is a triple board certified Hematologist & Medical Oncologist serving as Chief of Oncology Service at Baton Rouge General Hospital, and a social & news media personality known as 'TheOncDoc' with over half a million followers. He is an active participant for the White House Healthcare Leaders in Social Media Roundtable and national speaker. Dr. Juneja is the host of an innovative podcast called 'Target: Cancer' with distinguished academicians and celebrities around the country, and been featured in several articles including The Washington Post and guested on dozens of acclaimed podcasts and regional news channels (PBS, CBS, NBC, NPR). He is a Business Report's 40 under 40 recipient from his hometown of Baton Rouge, where he partners with the LA Department of Health and Mayor's office to optimize healthcare access and outreach. Dr. Juneja currently practices in his beloved hometown of Baton Rouge Louisiana with his wife Dr. Lauren and their three wild boys.
Crissy Kus, BSN, RN, BMTCN
Rayne H. Rouce, MD, BS
Associate Professor
Department of Pediatrics
Texas Children’s Cancer Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX
Rayne Rouce, MD, BS, is a Pediatric Hematologist and Oncologist at Texas Children's Cancer Center where she is a member of the Leukemia and Bone Marrow Transplant Programs.
She received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston, TX, then completed fellowship at Texas Children's Hospital. Dr. Rouce has spent the past several years of her career pioneering immunotherapy research for patients with refractory leukemia and lymphoma. Specifically, she works as part of a research program (The Center for Cell and Gene Therapy at Baylor College of Medicine) focused on translating targeted T cell therapies from the bench to bedside and has been involved in every aspect of CAR T cell development for clinical use. She has significant clinical experience in taking care of patients who have received CAR T cells and is passionate about ensuring patients and families understand this exciting new therapy.
Accreditation and Disclosure Information
Target Audience
This CE activity is intended for hematologic oncology clinicians who provide CAR-T therapy for individuals with aggressive B-cell lymphomas.
Educational Objectives
After completing this CE activity, the participant should be better able to:
- Assess the clinical implications of recent and emerging safety and efficacy data for CAR-T therapies
- Evaluate the implications of recent and emerging data for referring clinicians
- Respond to common questions from and misperceptions of referring clinicians
- Collaborate with the inter-professional team to facilitate logistics and access for referred patients
- Plan strategies to participate in effective shared care with referring clinicians
Accreditation, Support and Credit
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Support Statement
This CE activity is supported through educational grants from Bristol Myers Squibb and Kite, A Gilead Company.
Educational Parterner Statement
This activity is jointly provided by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.3 contact hour in the area of pharmacology.
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.10 CEU) of the Accreditation Council for Pharmacy Education.
AAPA Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 29, 2023. PAs should only claim credit commensurate with the extent of their participation.
Interprofessional Continuing Education(IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Planner/Presenter
Division Head ad Interim, Division of Cancer Medicine
Department Chair, Department of Lymphoma/Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Advisory Board/Consultant: AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Epizyme, Genentech/Roche, Genmab, Gilead, Karyopharm, Pharmacyclics/Janssen, Seagen, Spectrum.
Research Grant: 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD Serono, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceutical, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research
Research Grant: Actinium Pharmaceuticals, Inc, Amgen Inc., Celgene Corp., Johnson and Johnson, Inc., Miltenyi Biotec, Sanofi, Takeda Pharmaceutical Co.
Advisory Board/Consultant: Actinium Pharmaceuticals, Inc., Amgen Inc., Celgene Corp., Jazz Pharmaceuticals, Inc., Johnson and Johnson, Inc., Kite, Novartis, Sanofi, Takeda Pharmaceutical Co.
Advisory Board/Consultant for Daiichi Sankyo and Guardant 360.
Has no relevant financial relationship(s) with ineligible companies to disclose for this educational activity.
Advisory Board/Consultant for Novartis Pharmaceuticals Corporation and Pfizer Inc.
Research Grant from Tessa Therapeutics
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and The Leukemia & Lymphoma Society, the joint provider do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Nicole Dane via email at ndane@mlieducation.org
For Physicians, if requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
About this Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters,
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.